Gupta Suneel 4

Accession 0001104659-24-123807

CIK 0001377121other

Filed

Nov 26, 7:00 PM ET

Accepted

Nov 27, 7:09 PM ET

Size

25.9 KB

Accession

0001104659-24-123807

Form 4

Period: 2024-11-25

EVP Clinical Operations

Transactions

Exercise/Conversion
Stock Option (right to buy)
2024-11-25−45,000→ 0 total
Exercise: $8.02Exp: 2029-02-27→ Common Stock (45,000 underlying)
Exercise/Conversion
Common Stock
2024-11-25$8.02/sh+45,000$360,900→ 274,611 total
Exercise/Conversion
Common Stock
2024-11-26$12.17/sh+30,000$365,100→ 286,174 total
Sale
Common Stock
2024-11-26$45.50/sh−19,191$873,191→ 266,983 total
Exercise/Conversion
Common Stock
2024-11-25$7.38/sh+45,000$332,100→ 229,611 total
Exercise/Conversion
Common Stock
2024-11-25$7.80/sh+85,000$663,000→ 359,611 total
Exercise/Conversion
Stock Option (right to buy)
2024-11-25−85,000→ 0 total
Exercise: $7.80Exp: 2030-02-27→ Common Stock (85,000 underlying)
Sale
Common Stock
2024-11-25$46.04/sh−103,437$4,762,239→ 256,174 total
Exercise/Conversion
Common Stock
2024-11-26$12.17/sh+450$5,477→ 267,433 total
Exercise/Conversion
Stock Option (right to buy)
2024-11-25−45,000→ 0 total
Exercise: $7.38Exp: 2029-01-14→ Common Stock (45,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2024-11-26−450→ 93,300 total
Exercise: $12.17Exp: 2033-01-15→ Common Stock (450 underlying)
Exercise/Conversion
Stock Option (right to buy)
2024-11-26−30,000→ 93,750 total
Exercise: $12.17Exp: 2033-01-15→ Common Stock (30,000 underlying)

Footnotes (6)

[F1]Includes an aggregate of 1,326 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2024.
[F2]Sale to cover the exercise price of the options.
[F3]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.63 to $46.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
[F4]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.23 to $45.81. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
[F5]These stock options are fully vested.
[F6]The stock option vests in 48 equal monthly installments following the date of grant.

Documents

1 file

Protagonist Therapeutics, Inc

CIK 0001377121

Entity typeother